Sorafenib is an Inhibitor of UGT1A1 but is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

PURPOSE: Several case reports suggest sorafenib exposure and sorafenib-induced hyperbilirubinemia may be related to a (TA)(5/6/7) repeat polymorphism in UGT1A1*28. We hypothesized that sorafenib inhibits UGT1A1 and individuals carrying UGT1A1*28 and/or UGT1A9 variants experience greater sorafenib ex...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Peer, Cody J., Sissung, Tristan M., Kim, AeRang, Jain, Lokesh, Woo, Sukyung, Gardner, Erin R., Kirkland, C. Tyler, Troutman, Sarah M., English, Bevin C., Richardson, Emily D., Federspiel, Joel, Venzon, David, Dahut, William, Kohn, Elise, Kummar, Shivaani, Yarchoan, Robert, Giaccone, Giuseppe, Widemann, Brigitte, Figg, William D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2012
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6432766/
https://ncbi.nlm.nih.gov/pubmed/22307138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2484
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन